Email:
global@GCP-ClinPlus.com
We are excited to announce the official launch of a Phase 1 clinical trial of Treg cell therapy for Amyotrophic Lateral Sclerosis (ALS), sponsored by NovaBio Therapeutics, at the prestigious Tiantan Hospital (Capital Medical University Affiliated Beijing Tiantan Hospital).
On July 29, 2025, the study kickoff ceremony was held at Tiantan Hospital to mark the initiation of the NP001-ALS01 project—a collaborative effort among NovaBio Therapeutics, GCP ClinPlus, and Tiantan Hospital. This is the first project jointly implemented by the three parties, aiming to bring new hope to ALS patients through innovative cell therapy.
GCP ClinPlus is honored to be the trusted CRO partner for this important program. With a proven track record of over 50 cell and gene therapy studies, including multiple neurodegenerative disease trials, we bring deep scientific and operational expertise to ensure the successful execution of early-phase trials. Our long-standing relationships with leading neurology centers, including Tiantan Hospital, uniquely position us to accelerate clinical research in ALS and other rare neurological diseases.
About Tiantan Hospital:
Founded in 1956, Tiantan is a Class A tertiary general hospital and the national center for clinical neuroscience and neurological disease quality control in China. With over 500,000 neurology outpatient visits annually and the country's largest ALS patient cohort under active follow-up, Tiantan offers a world-class platform for translational research and clinical innovation. The hospital's newly established Rare Neurological Disease Clinical and Translational Center is committed to advancing partnerships that drive the development and clinical adoption of novel therapies for rare diseases.
We are proud to contribute to this important mission and look forward to the progress of this promising ALS program.